Article information
Full text is only aviable in PDF
Bibliografía general
[Acocella and Angel, 1986]
G. Acocella, J.H. Angel.
Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase.
Am Rev Respir Dis, 134 (1986), pp. 1.283-1.286
[Alzeer and Fitzgerald, 1993]
P.T.H. Alzeer, J.M. Fitzgerald.
Corticosteroid and tuberculosis: risk and use adjunt therapy.
Tubercle Lung Dis, 74 (1993), pp. 6-11
[American Thoracic Society, 1992]
American Thoracic Society.
Control of tuberculosis in the United States.
Am Rev Respir Dis, 146 (1992), pp. 1.623-1.633
[American Thoracic Society, 1966]
American Thoracic Society.
Treatment of drug resistant tuberculosis.
Am Rev Respir Dis, 94 (1966), pp. 125-127
[Anderews et al., 1980]
D.T. Anderews, P.Y. Schoenfeld, P.C. Hopewell, M.H. Humphreys.
Tuberculosis in patients with end-stage renal disease.
Am J Med, 68 (1980), pp. 59-65
[Arnau and Vallano, 1992]
J.M. Arnau, A. Vallano.
Fármacos antituberculosos.
Tratamiento de la infección y enfermedad tuberculosa, pp. 13-21
[ATS/ALA, 1990]
ATS/ALA.
Diagnostic standards and classification of tuberculosis, 142 (1990), pp. 725-735
[ATS/ALA, 1983]
ATS/ALA.
Treatment of tuberculosis and other micobacterial diseases, 127 (1983), pp. 790-796
[Baciewicz et al., 1987]
A.M. Baciewicz, T.H. Self, W.B. Bekemeyer.
Update on rifampicin drug interactions.
Arch Intern Med, 147 (1987), pp. 565-568
[Bennett et al., 1980]
W.M. Bennett, R.S. Muther, R.A. Parker, P. Feig, G. Morrison, T.A. Golper.
Drug therapy in renal failure: dosing guidelines for adults.
Ann Intern Med, 93 (1980), pp. 62-89
[Boque Genovard, 1988]
M.A. Boque Genovard.
Adenitis cervical por micobacterias oportunistas en la infancia.
An Esp Pediatr, 29 (1988), pp. 284-287
[BTS, 1993]
BTS.
Six months vs nine months of chemotherapy for tuberculosis of the lymph Mode: final results.
Thorax, 48 (1993), pp. 423
[BTS, 1990]
BTS.
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the Br Th Soc.
Thorax, 45 (1990), pp. 403-408
[Clancy et al., 1991]
L. Clancy, H.L. Rieder, D.A. Enarson, S. Spinaci.
Tuberculosis elimination in the countries of Europe and other industrialized countries.
Eur Respir J, 4 (1991), pp. 1.288-1.295
[Cohn et al., 1990]
D.L. Cohn, B.J. Catlin, K.L. Peterson, F.N. Judson, J.A. Sbarbaro.
A 62dose, 6-months therapy for pulmonary and extrapulmonary tuberculosis.
Ann Intern Med, 112 (1990), pp. 407-415
[Crofton, 1969]
J. Crofton.
Treatment of patients with drug-resistance in economically developed countries.
Tubercle, 50 (1969), pp. 65-68
[Cynamon and Klemens, 1989]
M.H. Cynamon, S.P. Klemens.
New antimycobacterial agents.
Clin Chest Med, 10 (1989), pp. 355-364
[David and Newman, 1971]
H.L. David, R. Newman.
Some observations on the genetics of isoniazid resistance in the tubercle bacilli.
ARRD, 104 (1971), pp. 508-515
[Davidson and Quoc Le, 1992]
P.T. Davidson, H. Quoc Le.
Drug treatment of tuberculosis.
Drug, 43 (1992), pp. 651-673
[De March Ayuela et al., 1992]
P. De March Ayuela, A. Espinar, A. Gatón, J.M. Pina, R. Rey, R. Vidal.
Quimioprofilaxis antituberculosa.
Recomendaciones SEPAR. Arch Bronconeumol, 28 (1992), pp. 270-277
[Ellard et al., 1993]
G.A. Ellard, M.J. Humphries, B.W. Allen.
Cerebrospinal fluid drug concentration and the treatment of meningeal tuberculosis.
Am Rev Respir Dis, 148 (1993), pp. 650-655
[Farga, 1992]
V. Farga.
Tuberculosis resistente.
Tuberculosis, pp. 179-187
[Farga et al., 1983]
V. Farga, P. Valenzuela, F. Mendoza, E. Torres, I. Icekson.
Quimioterapia de corta duración.
Estudios operacionales controlados en Chile. Bol Union Inter Tuber, 58 (1983), pp. 102-107
[Girling, 1984]
D.J. Girling.
Efectos adversos de los medicamentos antituberculosos.
Bol UICT, 59 (1984), pp. 153-164
[Girling, 1989]
D.J. Girling.
The chemotherapy of tuberculosis.
The biology of the mycobacteria. Vol. 3, pp. 285-323
[Grosset, 1990]
J. Grosset.
Regímenes actuales y nuevas drogas en quimioterapia y quimioprofilaxis de la tuberculosis.
BUICTER, 65 (1990), pp. 95-99
[Grosset, 1992]
J.H. Grosset.
Treatment of tuberculosis in HIV infection.
Tubercle, 73 (1992), pp. 378-383
[Grupo de Trabajo sobre Tuberculosis, 1992]
Grupo de Trabajo sobre Tuberculosis.
Consenso nacional para el control de la tuberculosis en España.
Med Clin (Bare), 98 (1992), pp. 24-31
[Harding and Bailey, 1988]
S.M. Harding, W.C. Bailey.
Chemotherapy of tuberculosis.
Tuberculosis, pp. 39-55
[Helbert et al., 1990]
M. Helbert, D. Robinson, D. Buchanan, E. Hellger, M. McCarthy, I. Brouwn.
Mycobacterial infection in patients infected with the human immunodeficiency virus.
Thorax, 45 (1990), pp. 45-48
[Israel et al., 1992]
H.L. Israel, J.E. Gottlieb, W.C. Maddrey.
Perspective: preventive isoniazid therapy and the liver.
Chest, 101 (1992), pp. 1.298-1.301
[Jindani et al., 1980]
A. Jindani, V.R. Aber, E.A. Edwards, D.A. Mitchison.
The early bacterial activity of drugs in patients with pulmonary tuberculosis.
Am Rev Respir Dis, 121 (1980), pp. 939-948
[Kucers and Bennet, 1987]
A. Kucers, N.M. Bennet.
Ciprofloxacin.
ofloxacin. The use of antibiotics, JB Lippincot, (1987), pp. 1.234-1.266
[Lalande et al., 1992]
V. Lalande, C. Truffot-Pernot, J.H. Grosset.
Powerful bactericidal activity of sprafloxacin against Mycobacterium tuberculosis in mice.
World Congress on Tuberculosis, (1992),
[March, 1989]
P. March.
De.
¿Dónde tratar a nuestros tuberculosos?. Arch Bronconeumol, 25 (1989), pp. 249-251
[March Ayuda and De., 1992]
P.De. March Ayuda.
Fracasos y recaídas. Retratamientos.
Tratamiento de la infección y enfermedad tuberculosa, pp. 133-141
[March and De., 1977]
P.De. March.
Terapéutica moderna de la tuberculosis.
Avances en Terapéutica, 9 (1977), pp. 48-86
[March and De., 1982]
P.De. March.
Tuberculosis y embarazo.
Problemática actual. Arch Bronconeumol, 18 (1982), pp. 256-264
[March Ayuela et al., 1970]
P.De March Ayuela, J. Tttrell Gumá.
Retratamiento del tuberculoso crónico con drogas de reserva.
Resultados tardíos en 76 observaciones controladas de uno a cuatro años. Enf Torax, 19 (1970), pp. 1.093-1.117
[Mitchison, 1969]
D.A. Mitchison.
What is drug resistance?.
Tubercle, 50 (1969), pp. 44-47
[Mitchison, 1985]
D.A. Mitchison.
The action of antituberculosis drug in short-course chemotherapy.
Tubercle, 66 (1985), pp. 219-225
[Mitchison and Nunn, 1986]
D.A. Mitchison, A.J. Nunn.
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.
Am Rev Respir Dis, 133 (1986), pp. 423-430
[Ortega Calderón, 1987]
A. Ortega Calderón.
Retratamiento en tuberculosis.
Rev Clin Esp, 280 (1987), pp. 269-274
[Piersimoni et al., 1992]
C. Piersimoni, V. Morbiducci, S. Bornigia, G. De Sio, G. Scalise.
In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
Am Rev Respir Dis, 146 (1992), pp. 1.445-1.447
[Pina Gutiérrez et al., 1989]
J.M. Pina Gutiérrez, R.M. Martí Bonet, J. Montoliu, R. Planas Vila, R. Vidal Pla.
Intolerancia i toxicitat dels farmacs antituberculosos.
Ann Med (Bare), 74 (1989), pp. 15-21
[Rey, 1990]
R. Rey.
The “flu like” syndrome in tuberculosis patients on treatment with ansamycin LM-427. The last fight against tuberculosis until elimination.
First European Workshop Organized by WHO and IUATLD, (1990),
[Rey, 1990]
R. Rey.
Tratamiento con rifabutina en pacientes con tuberculosis pulmonar inicial.
Comisión de Tratamiento. Bol UICTER, 65 (1990), pp. 47-49
[Rey and Espinar, 1987]
R. Rey, A. Espinar.
Normativas sobre el tratamiento de la enfermedad y la infección tuberculosa. Recomendaciones SEPAR.
Doyma, (1987),
[Sauret Valet, 1992]
J. Sauret Valet.
Tratamiento de la tuberculosis en situaciones especiales.
Tratamiento de la infección y enfermedad tuberculosa, pp. 113-120
[Schiff, 1982]
E.R. Schiff.
Hepatic injury caused by medicinal agents. En; Disease of the liver.
JB Lippincot, (1982), pp. 640-642
[Shimao, 1987]
T. Shimao.
Drug resistance in tuberculosis control.
Tubercle, 68 (1987), pp. 5-15
[Stead and Dutt, 1982]
W.W. Stead, A.K. Dutt.
Chemotherapy for tuberculosis today.
Am Rev RespirDis, 125 (1982), pp. 94-101
[Tuberculosis Unit, 1990]
Tuberculosis Unit.
WHO. Tuberculosis control and research strategy for the 1990s.
Report and recommendations of a WHO meeting, (1990),
[Tuberculosis Unit, 1991]
Tuberculosis Unit.
WHO. Division of comunicable disease.
Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes 1991 (WHO/TUB/91, 161), (1991),
[USPHS, 1990]
USPHS.
Tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity and acceptability.
Ann Intern Med, 112 (1990), pp. 397-406
[Vallejo and Starke, 1992]
J.G. Vallejo, J.R. Starke.
Tuberculosis and pregnancy.
Clin Chest Med, 13 (1992), pp. 693-707
[Vidal Pla and De Gracia Roldán, 1992]
R. Vidal Pla, X. De Gracia Roldán.
Tratamiento de la tuberculosis en la Infección por VIH.
Tratamiento de la infección y enfermedad tuberculosa, pp. 93-103
[Vidal et al., 1991]
R. Vidal, X. De Gracia, B. Gallego, C. Algueró, C. Bravo.
Hepatotoxicidad del tratamiento de la tuberculosis.
Med Clin (Bare), 97 (1991), pp. 481-485
[Vidal et al., 1986]
R. Vidal, J. De Gracia, J. Ruiz, E. Fité, E. Monsó, N. Martín.
Estudio controlado de 637 pacientes con tuberculosis.
Diagnóstico y resultados terapéuticos con esquemas de 9 y 6 meses. Med Clin (Barc), 87 (1986), pp. 368-370
[Van Scoy and Wilkowske, 1992]
R.E. Van Scoy, C.J. Wilkowske.
Antituberculous agents.
Mayo Clin Proc, 67 (1992), pp. 179-187
Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica
